small cell lung cancer
Conditions
Interventions
Case series:modified neoantigen reactive T cells
Sponsors
The First Affiliated Hospital of The Second Military Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed (included in the research center) as advanced small cell lung cancer, TNM stage as STAGE IIIb-IV; 2. Aged 18-75 years old; 3. Radiotherapy and chemotherapy were not effective, or chemotherapy was not suitable for or unwilling to radiotherapy, unwilling to other immunotherapy, at least one imaging measurable lesion.Expected survival >=3 months.Total bilirubin =50ml/min.
Exclusion criteria
Exclusion criteria: 1. Patients with HIV infection, hepatitis C virus (HCV) infection, uncontrolled coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that researchers consider not eligible for inclusion.Those with a history of bone marrow or organ transplantation; 2. People with coagulation disorders; 3. Subjects with immunodeficiency disease or autoimmune disease; 4. Patients who have had other immunotherapy within 1 month (such as immunocheckpoint inhibitor therapy, therapeutic antibody therapy, immunocell therapy and immunoregulator therapy); 5. May be allergic to immunotherapy; 6. Drug and alcohol abuse, clinical or psychological or social factors influence informed consent or research implementation; 7. Pregnant and lactating women; 8. Currently participating in or has participated in other clinical trials within a month; 9. Any uncertainties affecting patient safety or compliance; 10. Survivors of secondary brain metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of adverse events and specific laboratory abnormalities (CTCAE V4.03) in all treated subjects; | — |
Countries
China
Contacts
Public ContactWei Zhang
The First Affiliated Hospital of The Second Military Medical University
Outcome results
None listed